tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VTVT Stock Latest News

vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright
The FlyvTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright
8d ago
VTVT
vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi
PremiumThe Fly
vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi
8d ago
VTVT
Positive Outlook for vTv Therapeutics: Buy Rating on Cadisegliatin’s Promising Phase 3 Trial and Market Potential
PremiumRatings
Positive Outlook for vTv Therapeutics: Buy Rating on Cadisegliatin’s Promising Phase 3 Trial and Market Potential
1M ago
VTVT
vTv Therapeutics initiated with a Buy at BTIG
PremiumThe Fly
vTv Therapeutics initiated with a Buy at BTIG
1M ago
VTVT
Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment
PremiumRatings
Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment
2M ago
VTVT
vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)
PremiumThe FlyvTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)
2M ago
VTVT
vTv Therapeutics trading resumes
Premium
The Fly
vTv Therapeutics trading resumes
2M ago
VTVT
vTv Therapeutics trading halted, volatility trading pause
Premium
The Fly
vTv Therapeutics trading halted, volatility trading pause
2M ago
VTVT
vTv Therapeutics’ Promising Phase 3 Study on Cadisegliatin for Type 1 Diabetes
PremiumCompany Announcements
vTv Therapeutics’ Promising Phase 3 Study on Cadisegliatin for Type 1 Diabetes
2M ago
VTVT
vTv Therapeutics announces three appointments to Scientific Advisory Board
PremiumThe Fly
vTv Therapeutics announces three appointments to Scientific Advisory Board
3M ago
VTVT
vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders
PremiumThe Fly
vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders
3M ago
VTVT
vTv Therapeutics trading resumes
PremiumThe Fly
vTv Therapeutics trading resumes
3M ago
VTVT
vTv Therapeutics trading halted, volatility trading pause
PremiumThe FlyvTv Therapeutics trading halted, volatility trading pause
3M ago
VTVT
vTv Therapeutics to Join Morgan Stanley Conference
Premium
Company Announcements
vTv Therapeutics to Join Morgan Stanley Conference
4M ago
8K
VTVT
vTv Therapeutics Announces $80 Million Private Placement
Premium
Company Announcements
vTv Therapeutics Announces $80 Million Private Placement
4M ago
8K
VTVT
vTv Therapeutics announces $80M private placement
PremiumThe Fly
vTv Therapeutics announces $80M private placement
4M ago
VTVT
Optimistic Buy Rating for vTv Therapeutics Driven by Clinical Progress and Strategic Advancements
PremiumRatings
Optimistic Buy Rating for vTv Therapeutics Driven by Clinical Progress and Strategic Advancements
5M ago
VTVT
vTv Therapeutics announces USPTO allowance of patent covering cadisegliatin
PremiumThe Fly
vTv Therapeutics announces USPTO allowance of patent covering cadisegliatin
5M ago
VTVT
vTv Therapeutics announces first participant randomized in CATT1 Phase 3 trial
PremiumThe Fly
vTv Therapeutics announces first participant randomized in CATT1 Phase 3 trial
5M ago
VTVT
vTv Therapeutics’ Phase 3 Diabetes Trial: A Potential Game-Changer?
PremiumCompany AnnouncementsvTv Therapeutics’ Phase 3 Diabetes Trial: A Potential Game-Changer?
5M ago
VTVT
vTv Therapeutics Holds 2025 Annual Stockholders Meeting
Premium
Company Announcements
vTv Therapeutics Holds 2025 Annual Stockholders Meeting
7M ago
8K
VTVT
vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial
Premium
Company Announcements
vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial
7M ago
8K
VTVT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >